Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system

CONCLUSION: Gender differences existed in ADE signals related to Osimertinib. The higher risk of ADEs in male patients was lung diseases that seem more serious than those nail toxicities or skin problems that occurred in female patients. In order to ensure the safety of medication, we should be alert to the differences between different genders and take corresponding preventive measures to reduce the occurrence of serious ADEs.PMID:37515501 | DOI:10.1080/14740338.2023.2243220

Source: Expert Opinion on Drug Safety - July 29, 2023 Category: Drugs & Pharmacology Authors: Zhiping Li Wenbin Zou Jiao Yuan Yunxiang Zhong Zhiwen Fu Source Type: research